"Promising New Antibiotic Targets Drug-Resistant Gonorrhea in Phase 3 Trial"
In a large-scale clinical trial, the experimental drug zoliflodacin has been found to be just as effective as other frontline antibiotics in treating gonorrhea, a sexually transmitted infection that has become increasingly resistant to antibiotics. The drug, developed by Global Antibiotic Research & Development Partnership (GARDP), showed promising results in clearing infections and fending off drug-resistant strains. Pending validation by outside scientists and regulatory agencies, zoliflodacin could become the first new drug for gonorrhea in decades, offering a potential solution to the ongoing crisis of antibiotic resistance. GARDP has already obtained rights to commercialize the drug in most low- to middle-income countries, while Entasis Therapeutics will hold rights in major markets.
